KemPharm, a pharmaceutical company, completed the acquisition of Orphazyme, a biotechnology company, for $18m. “We are very pleased to have completed the Sale of Assets to KemPharm given the situation of Orphazyme under in-court restructuring, as the deal is able to satisfy our obligations towards creditors and employees and given that KemPharm has a special interest in taking ownership of arimoclomol and continued pursuit of developing arimoclomol in the hope of making it available for NPC patients," Georges Gemayel, Orphazyme Chairman.